Cover Image
Market Research Report

Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis B, HCV, HAV, HDV), Technology (ELISA, RDT, PCR, Transcription Mediated Amplification), End User (Hospitals, Diagnostic Laboratories, Blood Banks, Nursing Homes), Global Forecast to 2023

Published by MarketsandMarkets Product code 718223
Published Content info 113 Pages
Delivery time: 1-2 business days
Price
Back to Top
Hepatitis Test Solution/Diagnosis Market by Disease Type (Hepatitis B, HCV, HAV, HDV), Technology (ELISA, RDT, PCR, Transcription Mediated Amplification), End User (Hospitals, Diagnostic Laboratories, Blood Banks, Nursing Homes), Global Forecast to 2023
Published: October 2, 2018 Content info: 113 Pages
Description

"The hepatitis test solution/diagnosis market is projected to register a CAGR of 4.9%."

The hepatitis test solution/diagnosis market is expected to reach USD 3.37 billion by 2023 from USD 2.66 billion in 2018, growing at a CAGR of 4.9% during the forecast period. The growth of this market can be attributed to the high burden of hepatitis worldwide, benefits offered by point of care instruments & kits, and initiatives taken by government and non-government organizations. However, lack of mandate for NAT in developing countries and the high cost of NAT test are expected to restrain the growth of this market during the forecast period.

"The rapid diagnostics test segment of the hepatitis test solution/diagnosis market, by technology, is projected to grow at the highest CAGR in 2018."

By technology, the hepatitis test solution/diagnosis market is segmented into ELISA, rapid diagnostics test, PCR, INAAT, and other technologies. RDT is projected to grow at the highest CAGR during the forecast period. This growth is mainly attributed to the low cost of this test type, its high analytical sensitivity, and its ability to detect all known 11 subtypes of HBsAg.

"The hepatitis B segment is expected to account for the largest share of the market, by disease type, in 2018."

The market is classified on the basis of disease type into hepatitis B, hepatitis C, and other hepatitis disease. In terms of value, the hepatitis B segment is expected to account for the largest share of the market in 2018. This can primarily be attributed to the rising prevalence of hepatitis B, availability of a large number of hepatitis B diagnostic tests, and the increasing adoption of NAT test in HBV blood screening.

"North America to dominate the market in 2018."

North America is expected to account for the largest share of the global hepatitis test solution/diagnosis market in 2018. This is primarily attributed to factors such as rising adoption of advanced technologies, developed healthcare systems in the US and Canada, and the presence of a large number of leading national clinical laboratories. Followed by North America, Europe is expected to account for the second-largest share of the global hepatitis test solution/diagnosis market in 2018.

Break-up profile of primaries::

  • By Company Type- Tier 1-32%, Tier 2-42% and Tier 3-26%
  • By Designation-C-level-23%, D-level-35% and Others-42%
  • By Region-North America-39%, Europe-25%, Asia Pacific-26%, and RoW-10%

Abbott Laboratories (US), Roche (Switzerland), Bio-Rad (US), Siemens (Germany), DiaSorin (Italy), QIAGEN (Netherlands), Danaher (US), bioMerieux (France), and Grifols (Spain) are some of the key players operating in this market.

Research Coverage:

The hepatitis test solution/diagnosis market studied in this report is segmented by disease type, technology, end user, and region. The study tracks and analyzes competitive developments such as product launches; expansions; agreements, partnerships, and collaborations; and acquisitions. It also profiles the key players and their core competencies within the hepatitis test solution/diagnosis market.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on portfolios offered by the top players in the global hepatitis test solution/diagnosis market. The report analyzes the hepatitis test solution/diagnosis market by disease type, technology, end user, and region.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the hepatitis test solution/diagnosis market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for hepatitis test solution/diagnosis products across regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, and recent developments in the global hepatitis test solution/diagnosis market
  • Competitive Assessment: In-depth assessment of strategies, products, and manufacturing capabilities of the key players in the global hepatitis test solution/diagnosis market
Table of Contents
Product Code: MD 6643

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. YEARS COVERED FOR THE STUDY
  • 1.4. CURRENCY
  • 1.5. LIMITATIONS
  • 1.6. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. PRIMARY DATA
    • 2.1.1. KEY DATA FROM PRIMARY SOURCES
    • 2.1.2. KEY INDUSTRY INSIGHTS
  • 2.2. SECONDARY DATA
  • 2.3. KEY DATA FROM SECONDARY SOURCES
  • 2.4. MARKET SIZE ESTIMATION
  • 2.5. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.5.1. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. HEPATITIS TESTING: MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: HEPATITIS TESTING MARKET, BY DISEASE TYPE (2018)
  • 4.3. HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018 VS. 2023
  • 4.4. HEPATITIS TESTING MARKET, BY END USER, 2016-2023

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
    • 5.1.1. DRIVERS
      • 5.1.1.1. High burden of hepatitis
      • 5.1.1.2. Increasing blood transfusion and donations
      • 5.1.1.3. Benefits of PoC instruments & kits
      • 5.1.1.4. Awareness initiatives
    • 5.1.2. RESTRAINTS
      • 5.1.2.1. High Cost of NAT
      • 5.1.2.2. Lack of mandate for NAT in developing countries
    • 5.1.3. OPPORTUNITIES
      • 5.1.3.1. Emerging markets

6. HEPATITIS TESTING MARKET, BY DISEASE TYPE

  • 6.1. INTRODUCTION
  • 6.2. HEPATITIS B (HBV)
  • 6.3. HEPATITIS C (HCV)
  • 6.4. OTHER HEPATITIS DISEASES

7. HEPATITIS TESTING MARKET, BY TECHNOLOGY

  • 7.1. INTRODUCTION
  • 7.2. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
  • 7.3. RAPID DIAGNOSTIC TESTS (RDT)
  • 7.4. POLYMERASE CHAIN REACTION (PCR)
  • 7.5. ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY (INAAT)
  • 7.6. OTHER TECHNOLOGIES

8. HEPATITIS TESTING MARKET, BY END USER

  • 8.1. INTRODUCTION
  • 8.2. HOSPITAL & DIAGNOSTIC LABORATORIES
  • 8.3. BLOOD BANKS
  • 8.4. OTHER END USERS

9. HEPATITIS TESTING MARKET, BY REGION

  • 9.1. INTRODUCTION
  • 9.2. NORTH AMERICA
    • 9.2.1. US
    • 9.2.2. CANADA
  • 9.3. EUROPE
    • 9.3.1. GERMANY
    • 9.3.2. UK
    • 9.3.3. REST OF EUROPE
  • 9.4. ASIA PACIFIC
  • 9.5. REST OF THE WORLD

10. COMPETITIVE LANDSCAPE

  • 10.1. MARKET OVERVIEW
  • 10.2. MARKET RANKING ANALYSIS, 2017
  • 10.3. COMPETITIVE SITUATION AND TRENDS
    • 10.3.1. COLLABORATIONS, AGREEMENTS, AND PARTNERSHIPS
    • 10.3.2. PRODUCT LAUNCHES AND APPROVALS
    • 10.3.3. ACQUISITIONS

11. COMPANY PROFILES (Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*

  • 11.1. ABBOTT LABORATORIES, INC.
  • 11.2. ROCHE DIAGNOSTICS
  • 11.3. BIO-RAD LABORATORIES
  • 11.4. SIEMENS HEALTHINEERS
  • 11.5. DIASORIN
  • 11.6. QIAGEN
  • 11.7. DANAHER CORPORATION
  • 11.8. GRIFOLS
  • 11.9. BIOMERIEUX SA
  • 11.10. ORTHO CLINICAL DIAGNOSTICS (A PART OF THE CARLYLE GROUP)
  • 11.11. FUJIREBIO, INC. (A PART OF MIRACA GROUP)

*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

12. APPENDIX

  • 12.1. INSIGHTS OF INDUSTRY EXPERTS
  • 12.2. DISCUSSION GUIDE
  • 12.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.4. AVAILABLE CUSTOMIZATIONS
  • 12.5. RELATED REPORTS
  • 12.6. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: GLOBAL HEPATITIS PREVALENCE (MILLION PEOPLE APPROX.), 2015
  • TABLE 2: INCREASE IN VOLUNTARY NON-REMUNERATED BLOOD DONATIONS AND TOTAL BLOOD DONATIONS, 2008-2013
  • TABLE 3: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2016-2023 (USD MILLION)
  • TABLE 4: HEPATITIS B TESTING MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 5: NORTH AMERICA: HEPATITIS B TESTING MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 6: HEPATITIS C TESTING MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 7: NORTH AMERICA: HEPATITIS C TESTING MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 8: HEPATITIS TESTING MARKET FOR OTHER DISEASES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 9: NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER DISEASES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 10: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 11: HEPATITIS TESTING MARKET FOR ELISA, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 12: NORTH AMERICA: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 13: EUROPE: HEPATITIS TESTING MARKET FOR ELISA, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 14: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 15: NORTH AMERICA: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 16: EUROPE: HEPATITIS TESTING MARKET FOR RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 17: HEPATITIS TESTING MARKET FOR PCR, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 18: NORTH AMERICA: HEPATITIS TESTING MARKET FOR PCR, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 19: EUROPE: HEPATITIS TESTING MARKET FOR PCR, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 20: HEPATITIS TESTING MARKET FOR INAAT, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 21: NORTH AMERICA: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 22: EUROPE: HEPATITIS TESTING MARKET FOR INAAT, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 23: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 24: NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 25: EUROPE: HEPATITIS TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 26: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 27: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 28: NORTH AMERICA: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 29: EUROPE: HEPATITIS TESTING MARKET FOR HOSPITAL & DIAGNOSTIC LABS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 30: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 31: NORTH AMERICA: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 32: EUROPE: HEPATITIS TESTING MARKET FOR BLOOD BANKS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 33: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 34: NORTH AMERICA: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 35: EUROPE: HEPATITIS TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 36: HEPATITIS TESTING MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 37: NORTH AMERICA: HEPATITIS TESTING MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 38: NORTH AMERICA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2016-2023 (USD MILLION)
  • TABLE 39: NORTH AMERICA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 40: NORTH AMERICA: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 41: HAV AND HBV VACCINATION COVERAGE: US (2014-2016)
  • TABLE 42: US: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2016-2023 (USD MILLION)
  • TABLE 43: US: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 44: US: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 45: CANADA: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2016-2023 (USD MILLION)
  • TABLE 46: CANADA: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 47: CANADA: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 48: EUROPE: HEPATITIS TESTING MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 49: EUROPE: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2016-2023 (USD MILLION)
  • TABLE 50: EUROPE: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 51: EUROPE: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 52: GERMANY: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 53: GERMANY: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 54: UK: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 55: UK: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 56: ROE: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 57: ROE: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 58: ESTIMATED PREVALENCE OF CHRONIC HBV AND HCV: ASIA PACIFIC
  • TABLE 59: ASIA-PACIFIC: COST COVERAGE FOR DIAGNOSIS OF CHRONIC VIRAL HEPATITIS
  • TABLE 60: APAC: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2016-2023 (USD MILLION)
  • TABLE 61: APAC: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 62: APAC: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 63: ROW: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2016-2023 (USD MILLION)
  • TABLE 64: ROW: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2016-2023 (USD MILLION)
  • TABLE 65: ROW: HEPATITIS TESTING MARKET, BY END USER, 2016-2023 (USD MILLION)
  • TABLE 66: RANK OF COMPANIES IN THE HEPATITIS TESTING MARKET, 2017
  • TABLE 67: COLLABORATIONS, AGREEMENTS, AND PARTNERSHIPS
  • TABLE 68: PRODUCT LAUNCHES AND APPROVALS, 2015-2018
  • TABLE 69: ACQUISITIONS, 2015-2018

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 4: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION
  • FIGURE 6: HEPATITIS TESTING MARKET, BY DISEASE TYPE, 2018 VS. 2023
  • FIGURE 7: HEPATITIS TESTING MARKET, BY TECHNOLOGY, 2018 VS. 2023
  • FIGURE 8: HEPATITIS TESTING MARKET, BY END USER, 2018 VS. 2023
  • FIGURE 9: GEOGRAPHICAL SNAPSHOT OF THE HEPATITIS TESTING MARKET
  • FIGURE 10: HIGH BURDEN OF HEPATITIS & INITIATIVES TAKEN BY GOVERNMENT AND NON-GOVERNMENT ORGANIZATIONS-KEY FACTORS DRIVING MARKET GROWTH
  • FIGURE 11: HEPATITIS B SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2018
  • FIGURE 12: ELISA WILL CONTINUE TO DOMINATE THE HEPATITIS TESTING MARKET, BY TECHNOLOGY, IN 2023
  • FIGURE 13: HOSPITAL & DIAGNOSTIC LABORATORIES TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2018
  • FIGURE 14: HEPATITIS TESTING MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES
  • FIGURE 15: HEPATITIS TESTING MARKET: GEOGRAPHIC SNAPSHOT (2018)
  • FIGURE 16: NORTH AMERICA: MARKET SNAPSHOT
  • FIGURE 17: REPORTED ACUTE (NEW) CASES OF HEPATITIS C: US (2010-2016)
  • FIGURE 18: ASIA PACIFIC: HEPATITIS TESTING MARKET SNAPSHOT
  • FIGURE 19: KEY DEVELOPMENTS IN THE HEPATITIS TESTING MARKET BETWEEN 2015 AND 2017
  • FIGURE 20: ABBOTT: COMPANY SNAPSHOT (2017)
  • FIGURE 21: ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2017)
  • FIGURE 22: BIO-RAD: COMPANY SNAPSHOT (2017)
  • FIGURE 23: SIEMENS AG: COMPANY SNAPSHOT (2017)
  • FIGURE 24: DIASORIN: COMPANY SNAPSHOT (2017)
  • FIGURE 25: QIAGEN: COMPANY SNAPSHOT (2017)
  • FIGURE 26: DANAHER: COMPANY SNAPSHOT (2017)
  • FIGURE 27: GRIFOLS: COMPANY SNAPSHOT (2017)
  • FIGURE 28: BIOMERIEUX: COMPANY SNAPSHOT (2017)
  • FIGURE 29: MIRACA: COMPANY SNAPSHOT (2017)
Back to Top